Clinical Research Directory
Browse clinical research sites, groups, and studies.
Study of GSK3511294 in Healthy Chinese Participants
Sponsor: GlaxoSmithKline
Summary
This single dose pharmacokinetic (PK) study aims to investigate the PK, safety, tolerability and immunogenicity of two dose levels of GSK3511294 administered subcutaneously in Chinese healthy participants
Official title: An Open-label, Single Dose Study to Investigate the Pharmacokinetics, Safety, Tolerability and Immunogenicity of Two Dose Levels of GSK3511294 Administered Subcutaneously in Chinese Healthy Participants
Key Details
Gender
All
Age Range
18 Years - 45 Years
Study Type
INTERVENTIONAL
Enrollment
20
Start Date
2021-12-10
Completion Date
2022-12-23
Last Updated
2026-05-26
Healthy Volunteers
Yes
Conditions
Interventions
Depemokimab
Depemokimab was administered.
Locations (1)
GSK Investigational Site
Hangzhou, China